search
Back to results

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Primary Purpose

Healthy Volunteers, Diabetes Mellitus, Type 1

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
NNC0363-0845
Placebo (NNC0363-0845)
Insulin degludec
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteers

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Part 1 (healthy subjects):

  • Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Part 2 and 3 (subjects with type 1 diabetes mellitus):

  • Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
  • Aged 18-55 years (both inclusive) at the time of signing informed consent.
  • Diagnosed with type 1 diabetes mellitus 1 year or more prior to the day of screening.
  • Glycated haemoglobin (HbA1c) equal to or below 8.5%.
  • Fasting C-peptide below 0.30 nmol/L.
  • Considered to be generally healthy (except for type 1 diabetes mellitus and sequelae of diabetes which may only be of mild severity) based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion Criteria:

Part 1 (healthy subjects) Part 2 and Part 3 (subjects with type 1 diabetes mellitus):

- Male of reproductive age who or whose partner(s) is not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). Adequate contraceptive measures include that the male subject uses a condom during intercourse and that the partner practices adequate contraception (risk of pregnancy must be lower than 1%). In addition, subjects must not donate sperm for the duration of the trial.

Sites / Locations

  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part 1

Part 2

Part 3

Arm Description

Healthy volunteers will receive either NNC0363-0845 or placebo

Participants with T1D will receive either NNC0363-0845 or insulin degludec

Participants with T1D will receive NNC0363-0845

Outcomes

Primary Outcome Measures

Number of treatment-emergent adverse events (AEs)
Number of events
Number of treatment-emergent adverse events (AEs)
Number of events

Secondary Outcome Measures

Number of treatment-emergent hypoglycaemic episodes
Number of episodes
Number of treatment-emergent hypoglycaemic episodes
Number of episodes
Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose
pmol*h/L
Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose
pmol*h/L
Maximum observed serum NNC0363-0845 concentration after a single dose
pmol/L
Maximum observed serum NNC0363-0845 concentration after a single dose
pmol/L

Full Information

First Posted
September 24, 2020
Last Updated
June 25, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04569994
Brief Title
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
Official Title
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Healthy Subjects and in Subjects With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
September 30, 2020 (Actual)
Primary Completion Date
June 23, 2021 (Actual)
Study Completion Date
June 23, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is investigating the safety and tolerability of the new investigational product NNC0363-0845, its concentrations in the blood and its effect on the blood sugar for the treatment of diabetes. The study consists of 3 parts. The first part of the study is conducted in healthy people, while the second part involves people with type 1 diabetes (T1D). Part 3 of this trial involves also people with T1D. The study will test how NNC0363-0845 is tolerated by the body, how it is taken up in the blood, how long it stays there and how much the blood sugar is lowered. Healthy volunteers will either get NNC0363-0845 or placebo - which treatment is decided by chance. Participants with type 1 diabetes will either get NNC0363-0845 or insulin degludec (Tresiba®), also decided by chance. It is the first time that NNC0363-0845 is tested in humans. Participants will get one dose of NNC0363-0845 or placebo or insulin degludec injected into their left thigh. Participation in the study will last for up to 6 weeks. There will be one Informed Consent visit and 6 clinic visits with the study doctor. Healthy volunteers will have blood sampling to measure blood sugar and the concentration of the investigational product in the blood. Participants with type 1 diabetes will have a clamp experiment where the blood sugar is measured and controlled for up to 42 hours. For Part 3, the total duration of the trial for each individual is expected to be approximately 3-9 weeks. Participants cannot be in the study if the study doctor thinks that there are risks for their health. Women can only take part in the study if they are of non-child bearing potential.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteers, Diabetes Mellitus, Type 1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Part 1 will be a placebo-controlled trial in healthy subjects; Part 2 will be an active-controlled trial in subjects with T1D. Part 3 of this trial, will be an open-label, two-period cross-over, randomised, single dose trial in subjects with T1D.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Allocation
Randomized
Enrollment
68 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part 1
Arm Type
Experimental
Arm Description
Healthy volunteers will receive either NNC0363-0845 or placebo
Arm Title
Part 2
Arm Type
Experimental
Arm Description
Participants with T1D will receive either NNC0363-0845 or insulin degludec
Arm Title
Part 3
Arm Type
Experimental
Arm Description
Participants with T1D will receive NNC0363-0845
Intervention Type
Drug
Intervention Name(s)
NNC0363-0845
Intervention Description
A single dose administered s.c. (subcutaneously, under the skin)
Intervention Type
Drug
Intervention Name(s)
Placebo (NNC0363-0845)
Intervention Description
A single dose administered s.c.
Intervention Type
Drug
Intervention Name(s)
Insulin degludec
Intervention Description
A single dose administered s.c.
Primary Outcome Measure Information:
Title
Number of treatment-emergent adverse events (AEs)
Description
Number of events
Time Frame
Part 1 and 2: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10
Title
Number of treatment-emergent adverse events (AEs)
Description
Number of events
Time Frame
Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)
Secondary Outcome Measure Information:
Title
Number of treatment-emergent hypoglycaemic episodes
Description
Number of episodes
Time Frame
Part 1 and 2 From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10
Title
Number of treatment-emergent hypoglycaemic episodes
Description
Number of episodes
Time Frame
Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)
Title
Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose
Description
pmol*h/L
Time Frame
Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)
Title
Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose
Description
pmol*h/L
Time Frame
Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)
Title
Maximum observed serum NNC0363-0845 concentration after a single dose
Description
pmol/L
Time Frame
Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)
Title
Maximum observed serum NNC0363-0845 concentration after a single dose
Description
pmol/L
Time Frame
Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Part 1 (healthy subjects): Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening. Aged 18-55 years (both inclusive) at the time of signing informed consent. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Part 2 and 3 (subjects with type 1 diabetes mellitus): Male subject or female subject of non-child bearing potential. Non-child bearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening. Aged 18-55 years (both inclusive) at the time of signing informed consent. Diagnosed with type 1 diabetes mellitus 1 year or more prior to the day of screening. Glycated haemoglobin (HbA1c) equal to or below 8.5%. Fasting C-peptide below 0.30 nmol/L. Considered to be generally healthy (except for type 1 diabetes mellitus and sequelae of diabetes which may only be of mild severity) based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator Exclusion Criteria: Part 1 (healthy subjects) Part 2 and Part 3 (subjects with type 1 diabetes mellitus): - Male of reproductive age who or whose partner(s) is not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice). Adequate contraceptive measures include that the male subject uses a condom during intercourse and that the partner practices adequate contraception (risk of pregnancy must be lower than 1%). In addition, subjects must not donate sperm for the duration of the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency and Medical Writing Office (1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Mainz
ZIP/Postal Code
55116
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Learn more about this trial

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

We'll reach out to this number within 24 hrs